Gene therapy for dyslipidemia: clinical prospects

Area of Science:

• Cardiovascular Medicine
• Genetics
• Metabolic Disorders

Background:

• Current treatments for lipid disorders are insufficient for many patients with severe conditions.
• Dyslipidemias, including low high-density lipoprotein (HDL) cholesterol, represent a significant unmet medical need.
• Molecular disorders of lipoprotein metabolism require innovative therapeutic strategies.

Purpose of the Study:

• To explore gene therapy as a novel treatment for severe dyslipidemias.
• To identify specific monogenic lipoprotein disorders amenable to gene therapy.
• To investigate gene therapy applications for raising HDL cholesterol and managing combined hyperlipidemia.

Main Methods:

• Review of current literature on gene therapy applications in lipid metabolism.
• Identification of monogenic disorders (e.g., homozygous familial hypercholesterolemia, familial lipoprotein lipase deficiency) as targets.
• Exploration of strategies involving apolipoprotein A-I and apoE gene expression.

Main Results:

• Gene therapy is a logical approach for monogenic lipoprotein disorders with inadequate current treatments.
• Gene therapy can be utilized to increase apolipoprotein A-I for raising HDL cholesterol.
• Gene therapy targeting apoE may offer a strategy for severe combined hyperlipidemia.

Conclusions:

• Gene therapy holds significant potential for treating severe dyslipidemias.
• Advancements in vector technology are crucial for clinical translation.
• Gene therapy is anticipated to become a clinical reality for severe dyslipidemias with further development.